Your browser doesn't support javascript.
loading
Early experimental COVID-19 therapies: associations with length of hospital stay, mortality and related costs.
Vernaz, Nathalie; Agoritsas, Thomas; Calmy, Alexandra; Gayet-Ageron, Angèle; Gold, Gabriel; Perrier, Arnaud; Picard, Fabienne; Prendki, Virginie; Reny, Jean-Luc; Samer, Caroline; Stirnemann, Jérôme; Vetter, Pauline; Zanella, Marie-Céline; Zekry, Dina; Baggio, Stéphanie.
Afiliación
  • Vernaz N; Medical Directorate, Finance Directorate, Geneva University Hospitals, Geneva University, Switzerland.
  • Agoritsas T; Division of General Internal Medicine and Division of Clinical Epidemiology, University Hospitals of Geneva, Switzerland / Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.
  • Calmy A; Division of Infectious Diseases, HIV/AIDS Unit, Geneva University Hospitals, Switzerland.
  • Gayet-Ageron A; CRC and Division of Clinical Epidemiology, Department of Health and Community Medicine, University of Geneva and University Hospitals of Geneva, Switzerland.
  • Gold G; Service of Geriatrics, Department of Internal Medicine Rehabilitation and Geriatrics, University Hospitals and University of Geneva, Switzerland.
  • Perrier A; Medical Directorate, University of Geneva and University Hospitals of Geneva, Geneva, Switzerland / Department of General Internal Medicine, Geneva University Hospitals, Switzerland.
  • Picard F; Division of Neurology, Department of Clinical Neurosciences, University of Geneva and University Hospitals of Geneva, Switzerland.
  • Prendki V; Division of Internal Medicine for the Aged, University of Geneva and University Hospitals of Geneva, Thônex, Switzerland.
  • Reny JL; Department of General Internal Medicine, Geneva University Hospitals, Switzerland.
  • Samer C; Division of Clinical Pharmacology and Toxicology, Geneva University Hospitals, Switzerland.
  • Stirnemann J; Department of General Internal Medicine, Geneva University Hospitals, Switzerland.
  • Vetter P; Geneva Centre for Emerging Viral Diseases, Geneva University Hospitals, Switzerland.
  • Zanella MC; Division of Infectious Diseases, Geneva University Hospitals, Switzerland.
  • Zekry D; Division of Internal Medicine for the Aged, University of Geneva and University Hospitals of Geneva, Thônex, Switzerland.
  • Baggio S; Division of Prison Health, University of Geneva and University Hospitals of Geneva, Thônex, Switzerland / Office of Corrections, Department of Justice and Home Affairs of the Canton of Zurich, Zurich, Switzerland.
Swiss Med Wkly ; 150: w20446, 2020 12 14.
Article en En | MEDLINE | ID: mdl-33382449

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 1_ASSA2030 / 2_ODS3 / 4_TD / 6_ODS3_enfermedades_notrasmisibles / 7_ODS3_muertes_prevenibles_nacidos_ninos Problema de salud: 1_financiamento_saude / 2_muertes_prevenibles / 4_covid_19 / 4_pneumonia / 6_other_respiratory_diseases / 7_non_communicable_diseases Asunto principal: Antivirales / Ritonavir / Lopinavir / COVID-19 / Tratamiento Farmacológico de COVID-19 / Hidroxicloroquina Tipo de estudio: Health_economic_evaluation / Observational_studies / Risk_factors_studies Límite: Aged80 Idioma: En Revista: Swiss Med Wkly Asunto de la revista: MEDICINA Año: 2020 Tipo del documento: Article País de afiliación: Suiza

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 1_ASSA2030 / 2_ODS3 / 4_TD / 6_ODS3_enfermedades_notrasmisibles / 7_ODS3_muertes_prevenibles_nacidos_ninos Problema de salud: 1_financiamento_saude / 2_muertes_prevenibles / 4_covid_19 / 4_pneumonia / 6_other_respiratory_diseases / 7_non_communicable_diseases Asunto principal: Antivirales / Ritonavir / Lopinavir / COVID-19 / Tratamiento Farmacológico de COVID-19 / Hidroxicloroquina Tipo de estudio: Health_economic_evaluation / Observational_studies / Risk_factors_studies Límite: Aged80 Idioma: En Revista: Swiss Med Wkly Asunto de la revista: MEDICINA Año: 2020 Tipo del documento: Article País de afiliación: Suiza
...